N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1.95p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.07
  • 52 Week Low: 1.90
  • Currency: UK Pounds
  • Shares Issued: 233.78m
  • Volume: 105,531
  • Market Cap: £4.56m

N4 Pharma reduces losses as Nuvec development continues

By Josh White

Date: Thursday 29 Sep 2022

LONDON (ShareCast) - (Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.
The AIM-traded firm, which is still pre-revenue, said research and development and general expenditure was in line with budget.

Its cash position remained "strong" at period end on 30 June, totalling £1.58m, down from £1.78m at the end of December but also in line with budget.

On the operational front, N4 said it had identified a number of "exciting opportunities" in the period for progression into phase 1 clinical trials in oncology and siRNA delivery.

Studies conducted with Nanomerics evaluating the potential of 'Nuvec' as a nano-carrier of a DNA plasmid expressing TNFalpha - a cytokine with immune-modulating properties against tumours - demonstrated a significant inhibition of tumour growth derived from a human cell line.

Positive preliminary results were also received from ongoing oral studies undertaken at the University of Queensland, showing Nuvec delivered orally transfected cells in the small intestine.

Nuvec patents were granted in the US and China in the half-year, with the company now having "strong" intellectual property protection in "key territories" globally.

"We have continued to make excellent progress in the period and have refined our focus in line with changing market conditions to provide us with the best opportunities to progress Nuvec into the clinic," said chief executive officer Nigel Theobald.

"Cash expenditure has been tightly controlled to allow us to maximise outcomes whilst preserving our cash resource as far as possible.

"I look forward with optimism to the excellent progress we have made continuing throughout the remainder of the financial year."

At 0916 BST, shares in N4 Pharma were up 10.67% at 1.9921p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 1.95p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.07
52 Week Low 1.90
Volume 105,531
Shares Issued 233.78m
Market Cap £4.56m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
26.58% below the market average26.58% below the market average26.58% below the market average26.58% below the market average26.58% below the market average
54.39% below the sector average54.39% below the sector average54.39% below the sector average54.39% below the sector average54.39% below the sector average
Value
26.58% below the market average26.58% below the market average26.58% below the market average26.58% below the market average26.58% below the market average
54.39% below the sector average54.39% below the sector average54.39% below the sector average54.39% below the sector average54.39% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for 27-Jan-2023

Time Volume / Share Price
16:35 55 @ 2.00p
16:35 2,631 @ 1.90p
16:35 90 @ 1.90p
14:12 191 @ 1.90p
14:12 102,564 @ 1.95p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page